Stock Price Forecast

March 2, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Albireo Pharma Inc chart...

About the Company

Albireo Pharma is a clinical-stage biopharmaceutical company focused on the development of novel bile acid modulators to treat rare pediatric and adult liver diseases, and other adult liver diseases and disorders. Albireo's lead product candidate, odevixibat, is being developed to treat rare pediatric cholestatic liver diseases with Phase 3 pivotal trials in PFIC, Alagille syndrome and biliary atresia. The Company completed IND-enabling studies for new preclinical candidate A3907 this year and plans to advance development in adult liver disease. Albireo was spun out from AstraZeneca in 2008 and is headquartered in Boston, Massachusetts, with its key operating subsidiary in Gothenburg, Sweden. The Boston Business Journal named Albireo one of the 2020 Best Places to Work in Massachusetts for the second consecutive year.

CEO

Ronald Cooper

Exchange

NASDAQ

Website

www.albireopharma.com

$13M

Total Revenue

130

Employees

$914M

Market Capitalization

-6.36

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ALBO News

FDA Approves Mirum's Livmarli For Liver Disease In Kids As Young As 5 Years: Analyst Bullish On Label Expansion Strategy

14d ago, source:

FDA approves Livmarli by Mirum Pharmaceuticals for cholestatic pruritus in PFIC patients ≥5 years old. Data from Phase 3 MARCH study. Analysts bullish on broader coverage in 2024, with price target ...

Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer

10d ago, source:

Industry veteran with late-stage clinical development, medical affairs, and regulatory experience; well-positioned to advance losmapimod towards ...

Chutes & Ladders—Bayer undergoes leadership shake-up

6d ago, source: FierceBiotech

Bayer’s pharmaceutical reinvention is continuing with a pair of new title additions for two members of the leadership team.

Ipsen files patent for cancer therapy using EZH2 inhibitor for ini1-negative tumors

2d ago, source: Pharmaceutical Technology

Discover Ipsen SA's groundbreaking patent for treating INI1-negative tumors like rhabdoid tumors with EZH2 inhibitors. Learn about the dosage ranges and specific dosing regimens outlined in the patent ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...